Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3142516#aggregation> ?p ?o. }
Showing items 1 to 40 of
40
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B418930.
- aggregation creator B418931.
- aggregation creator B418932.
- aggregation creator B418933.
- aggregation creator B418934.
- aggregation creator B418935.
- aggregation creator B418936.
- aggregation creator B418937.
- aggregation creator B418938.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 3142516.bibtex.
- aggregation hasFormat 3142516.csv.
- aggregation hasFormat 3142516.dc.
- aggregation hasFormat 3142516.didl.
- aggregation hasFormat 3142516.doc.
- aggregation hasFormat 3142516.json.
- aggregation hasFormat 3142516.mets.
- aggregation hasFormat 3142516.mods.
- aggregation hasFormat 3142516.rdf.
- aggregation hasFormat 3142516.ris.
- aggregation hasFormat 3142516.txt.
- aggregation hasFormat 3142516.xls.
- aggregation hasFormat 3142516.yaml.
- aggregation isPartOf urn:issn:1745-6215.
- aggregation language "eng".
- aggregation rights "I have retained and own the full copyright for this publication".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial".
- aggregation abstract "Background: Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such as hepatic resection and liver transplantation. A majority of patients have locally advanced, liver restricted disease (Barcelona Clinic Liver Cancer (BCLC) staging system intermediate stage). Transarterial loco regional treatment modalities offer palliative treatment options for these patients; transarterial chemoembolization (TACE) is the current standard treatment. During TACE, a catheter is advanced into the branches of the hepatic artery supplying the tumor, and a combination of embolic material and chemotherapeutics is delivered through the catheter directly into the tumor. Yttrium-90 radioembolization (Y-90-RE) involves the transarterial administration of minimally embolic microspheres loaded with Yttrium-90, a beta-emitting isotope, delivering selective internal radiation to the tumor. Y-90-RE is increasingly used in clinical practice for treatment of intermediate stage hepatocellular carcinoma, but its efficacy has never been prospectively compared to that of the standard treatment (TACE). In this study, we describe the protocol of a multicenter randomized controlled trial aimed at comparing the effectiveness of TACE and Y-90-RE for treatment of patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma. Methods/design: In this pragmatic randomized controlled trial, 140 patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma, with Eastern Cooperative Oncology Group performance status 0 to 1 and Child-Pugh A to B will be randomly assigned to either Y-90-RE or TACE with drug eluting beads. Patients assigned to Y-90-RE will first receive a diagnostic angiography, followed by the actual transarterial treatment, which can be divided into two sessions in case of bilobar disease. Patients assigned to TACE will receive a maximum of three consecutive transarterial treatment sessions. Patients will undergo structural follow-up for a timeframe of two years post treatment. Post procedural magnetic resonance imaging (MRI) will be performed at one and three months post trial entry and at three-monthly intervals thereafter for two years to assess tumor response. Primary outcome will be time to progression. Secondary outcomes will be overall survival, tumor response according to the modified RECIST criteria, toxicities/adverse events, treatment related effect on total liver function, quality of life, treatment-related costs and cost-effectiveness.".
- aggregation authorList BK739589.
- aggregation volume "13".
- aggregation aggregates 3159192.
- aggregation isDescribedBy 3142516.
- aggregation similarTo 1745-6215-13-144.
- aggregation similarTo LU-3142516.